Ipsen

Valuation Analysis

About the Company

Ipsen en bref

Ipsen (IPN.PA) is currently trading at 167,20 € with a market capitalization of 12,0 Md €. The trailing P/E ratio stands at 27.01x, with a forward P/E of 12.09x. The 52-week range spans from 103,20 € to 174,00 €; the current price is 3.9% below the yearly high. Year-over-year revenue growth stands at +18.7%. The net profit margin stands at 11.94%.

💰 Dividende

Ipsen pays an annual dividend of 1,60 € per share, representing a yield of 0.96%. The payout ratio stands at 25.89%.

📊 Avis des analystes

15 analystes évaluent Ipsen (IPN.PA) au consensus : Acheter. L'objectif de cours moyen est de 161,67 €, soit un potentiel de -3.31% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 117,00 € à 235,00 €.

Ipsen : la thèse d'investissement en détail

Ipsen (IPN.PA) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in France. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 18.7% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 81.01%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Valorisation en contexte

The PEG ratio at 1.48 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 8.79x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 12.09x is meaningfully below the trailing 27.01x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 90.4% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Ipsen?

Compare top-rated brokers — low fees, trusted providers, fully regulated.